Clinical Trials

Teva to discontinue ENFORCE program for fremanezumab due to futility

Teva Pharmaceutical Industries said that it will stop an ongoing clinical development program of its humanized monoclonal antibody fremanezumab in cluster headaches due to futility.

Lilly’s Taltz meets primary endpoint in phase 3 nr-axSpA trial

Eli Lilly and Company (Lilly) has announced that its psoriatic arthritis drug Taltz (ixekizumab) succeeded in a phase 3 trial in patients with non-radiographic axial spondyloarthritis (nr-axSpA).

Forbius announces first patient dosed in phase 2a EGFR-overexpressing TNBC trial of AVID100

Forbius, a clinical-stage company that develops novel biologics for the treatment of cancer and fibrosis, announced that the first patient has been dosed in a Phase 2a triple negative breast cancer (TNBC) clinical trial with AVID100, a novel, tumor-specific anti-epidermal growth factor receptor (EGFR) antibody-drug conjugate (ADC).

Pfizer, Lilly’s painkiller tanezumab shows mixed results in phase 3 osteoarthritis trial

Pfizer and Eli Lilly’s phase 3 study has showed mixed results of painkiller tanezumab in the treatment of patients with osteoarthritis (OA).

Alnylam initiates ILLUMINATE-B phase 3 pediatric study of Lumasiran to treat primary hyperoxaluria type 1

Alnylam Pharmaceuticals has initiated ILLUMINATE-B, a global Phase 3 pediatric study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1 (PH1).

Gilead Sciences and Novo Nordisk announce intent to initiate a clinical collaboration in NASH

Gilead Sciences, Inc. and Novo Nordisk A/S today announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH).

Janssen’s HIV drug SYMTUZA yields positive results in DIAMOND trial

Janssen Pharmaceutical said that a phase 3 trial evaluating SYMTUZA (darunavir 800mg, cobicistat 150mg, emtricitabine 200mg and tenofovir alafenamide 10mg D/C/F/TAF) showed that a high percentage of HIV patients recorded an undetectable viral load through 48 weeks after rapid initiation of the drug.

Moleculin announces agreement with Emory University to conduct pediatric brain tumor trial

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has entered into an agreement with Emory University to conduct a Phase 1 clinical trial of WP1066 in children with recurrent or refractory malignant brain tumors.

Poxel reports positive top-line results for Imeglimin phase 3 trial in Japan

POXEL and Sumitomo Dainippon Pharma announced positive top-line Phase 3 data results for the Imeglimin TIMES 1 trial for the treatment of type 2 diabetes in Japan.